Azazel (A580372) is 2 years old, strong, intelligent and calm, but now and then still has moments of puppy goofiness. He loves treats and toys. Azazel will be calm and controlled one moment, and in ...

Natalia Almada, Justin Chang and Jennie Livingston will judge the U.S. documentary competition for the final fest in Park City. By Mia Galuppo Senior Entertainment Reporter Leading the U.S. dramatic ...

The FDA has approved trastuzumab deruxtecan (T-DXd; Enhertu, Daiichi Sankyo/AstraZeneca) in combination with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast ...

T-DXd significantly improves progression-free and overall survival compared to T-DM1 in HER2-positive metastatic breast cancer, with a favorable safety profile. Real-world data show T-DXd's ...

Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast ...

VRC Derby contender Azazel pictured winning the Geelong Classic (2200m) on Thursday of last week. The three-year-old got his early education in Hastings. Azazel, one of the leading chances in today’s ...

Azazel won on debut at Seymour last month before finishing only a length from the winner in the Listed Super Impose Stakes at his second outing. The Mark Walker-trained three-year-old did best in the ...

Azazel has firmed in betting for the Victoria Derby following his narrow Listed Geelong Classic victory on Thursday afternoon. The Mark Walker-trained galloper moved to $7 for the Derby after edging ...

BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage breast cancer settings in back-to-back ...